Literature DB >> 2295878

Synergistic antitumor activity of tumor-infiltrating lymphocytes, interleukin 2, and local tumor irradiation. Studies on the mechanism of action.

R B Cameron1, P J Spiess, S A Rosenberg.   

Abstract

The adoptive transfer of tumor-infiltrating lymphocytes (TIL) with the concomitant administration of IL-2 has been shown to mediate the regression of established 6- and 14-d murine hepatic and pulmonary metastases. For successful immunotherapy with TIL, however, pretreatment with either cyclophosphamide (CP) or whole body irradiation (WBX) was required. The exact mechanism of CP and WBX augmentation of TIL antitumor activity remains unknown, but the elimination of Ts cells has been frequently invoked as an explanation. To address this possibility and to determine if local tumor irradiation (LTX) could synergize with TIL as well as WBX, we investigated the effect of LTX on the therapeutic efficacy of TIL and IL-2 in the treatment of multiple 7-d murine hepatic metastases. Experiments studying the treatment of a weakly immunogenic murine adenocarcinoma, MC-38, showed prolonged survival of mice treated with the combination of IL-2, TIL, and either LTX or WBX, compared with treatment with radiation alone or radiation plus IL-2 controls (p less than 0.0001). In addition, therapy with LTX and IL-2 prolonged survival, compared with LTX administration alone, whereas therapy with WBX combined with IL-2 did not alter survival. This augmentation of TIL-mediated antitumor activity was dependent on the dose of radiation used. To assess the possibility that tumor-associated Ts cells inhibit the function of adoptively transferred TIL in animals with 7-d metastatic tumor and are eliminated by WBX and LTX, we repeated the above experiments leaving some tumor unirradiated. Mice underwent either LTX or limited LTX, which included only the right side of the liver (LTX1/2). The number of right- and left-sided metastases were then individually counted. These studies showed that the reduction in the number of right-sided metastases was identical between the two groups and that the presence of left-sided tumor in the LTX1/2 group did not suppress the observed antitumor activity of TIL against irradiated tumor. Additional evidence against the elimination of suppressor cells as an important mechanism in radiation-induced augmentation of TIL antitumor activity was provided by experiments studying the effectiveness of TIL in thymectomized, lethally irradiated, and reconstituted B mice. Unless CP was administered before the adoptive transfer of TIL, therapy with IL-2 and TIL in these B mice was ineffective in the absence of demonstrable T lymphocytes.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2295878      PMCID: PMC2187667          DOI: 10.1084/jem.171.1.249

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  15 in total

1.  Gamma-irradiation facilitates the expression of adoptive immunity against established tumors by eliminating suppressor T cells.

Authors:  R J North
Journal:  Cancer Immunol Immunother       Date:  1984       Impact factor: 6.968

2.  Differences in the effects of host suppression on the adoptive immunotherapy of subcutaneous and visceral tumors.

Authors:  A E Chang; S Y Shu; T Chou; R Lafreniere; S A Rosenberg
Journal:  Cancer Res       Date:  1986-07       Impact factor: 12.701

3.  A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.

Authors:  S A Rosenberg; M T Lotze; L M Muul; A E Chang; F P Avis; S Leitman; W M Linehan; C N Robertson; R E Lee; J T Rubin
Journal:  N Engl J Med       Date:  1987-04-09       Impact factor: 91.245

4.  Tumor-derived interleukin-2-dependent lymphocytes in adoptive immunotherapy of lung cancer.

Authors:  R L Kradin; L A Boyle; F I Preffer; R J Callahan; M Barlai-Kovach; H W Strauss; S Dubinett; J T Kurnick
Journal:  Cancer Immunol Immunother       Date:  1987       Impact factor: 6.968

5.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

6.  A novel approach to the generation and identification of experimental hepatic metastases in a murine model.

Authors:  R Lafreniere; S A Rosenberg
Journal:  J Natl Cancer Inst       Date:  1986-02       Impact factor: 13.506

7.  Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness.

Authors:  A H Rook; J H Kehrl; L M Wakefield; A B Roberts; M B Sporn; D B Burlington; H C Lane; A S Fauci
Journal:  J Immunol       Date:  1986-05-15       Impact factor: 5.422

8.  Cyclophosphamide-facilitated adoptive immunotherapy of an established tumor depends on elimination of tumor-induced suppressor T cells.

Authors:  R J North
Journal:  J Exp Med       Date:  1982-04-01       Impact factor: 14.307

9.  Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth.

Authors:  J H Kehrl; L M Wakefield; A B Roberts; S Jakowlew; M Alvarez-Mon; R Derynck; M B Sporn; A S Fauci
Journal:  J Exp Med       Date:  1986-05-01       Impact factor: 14.307

10.  Regression of established pulmonary metastases and subcutaneous tumor mediated by the systemic administration of high-dose recombinant interleukin 2.

Authors:  S A Rosenberg; J J Mulé; P J Spiess; C M Reichert; S L Schwarz
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  31 in total

Review 1.  Combining immunotherapy and radiotherapy in lung cancer.

Authors:  Neeraj Bhalla; Rachel Brooker; Michael Brada
Journal:  J Thorac Dis       Date:  2018-05       Impact factor: 2.895

2.  The intersection of radiotherapy and immunotherapy: mechanisms and clinical implications.

Authors:  Michael Spiotto; Yang-Xin Fu; Ralph R Weichselbaum
Journal:  Sci Immunol       Date:  2016-09-30

3.  Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo.

Authors:  Chengwen Liu; Carol M Lewis; Yanyan Lou; Chunyu Xu; Weiyi Peng; Yan Yang; Alexander H Gelbard; Gregory Lizée; Dapeng Zhou; Willem W Overwijk; Patrick Hwu
Journal:  J Immunother       Date:  2012-04       Impact factor: 4.456

4.  Antitumor immunity induced after α irradiation.

Authors:  Jean-Baptiste Gorin; Jérémie Ménager; Sébastien Gouard; Catherine Maurel; Yannick Guilloux; Alain Faivre-Chauvet; Alfred Morgenstern; Frank Bruchertseifer; Michel Chérel; François Davodeau; Joëlle Gaschet
Journal:  Neoplasia       Date:  2014-04       Impact factor: 5.715

5.  A phase I study of nonmyeloablative chemotherapy and adoptive transfer of autologous tumor antigen-specific T lymphocytes in patients with metastatic melanoma.

Authors:  Mark E Dudley; John R Wunderlich; James C Yang; Patrick Hwu; Douglas J Schwartzentruber; Suzanne L Topalian; Richard M Sherry; Francesco M Marincola; Susan F Leitman; Claudia A Seipp; Linda Rogers-Freezer; Kathleen E Morton; Azam Nahvi; Sharon A Mavroukakis; Donald E White; Steven A Rosenberg
Journal:  J Immunother       Date:  2002 May-Jun       Impact factor: 4.456

6.  Cytotoxic T-lymphocyte epitope immunodominance in the control of choroid plexus tumors in simian virus 40 large T antigen transgenic mice.

Authors:  T D Schell; L M Mylin; I Georgoff; A K Teresky; A J Levine; S S Tevethia
Journal:  J Virol       Date:  1999-07       Impact factor: 5.103

7.  DNA Vaccines for Prostate Cancer.

Authors:  Douglas G McNeel; Jordan T Becker; Laura E Johnson; Brian M Olson
Journal:  Curr Cancer Ther Rev       Date:  2012-11-01

Review 8.  Combining brachytherapy and immunotherapy to achieve in situ tumor vaccination: A review of cooperative mechanisms and clinical opportunities.

Authors:  Ravi B Patel; Claire C Baniel; Raghava N Sriramaneni; Kristin Bradley; Stephanie Markovina; Zachary S Morris
Journal:  Brachytherapy       Date:  2018-08-02       Impact factor: 2.362

9.  Radiotherapy augments the immune response to prostate cancer in a time-dependent manner.

Authors:  Timothy J Harris; Edward L Hipkiss; Scott Borzillary; Satoshi Wada; Joseph F Grosso; Hung-Rong Yen; Derese Getnet; Tullia C Bruno; Monica V Goldberg; Drew M Pardoll; Theodore L DeWeese; Charles G Drake
Journal:  Prostate       Date:  2008-09-01       Impact factor: 4.104

10.  Effects of tumor irradiation on host T-regulatory cells and systemic immunity in the context of adoptive T-cell therapy in mice.

Authors:  Shuang Wei; Martin U Egenti; Seagal Teitz-Tennenbaum; Weiping Zou; Alfred E Chang
Journal:  J Immunother       Date:  2013-02       Impact factor: 4.456

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.